Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Grigorios Siokas, the Chief Executive Officer of Cosmos Health Inc. (NASDAQ:COSM), has acquired 79,254 shares of the company through a debt exchange agreement. The micro-cap healthcare company, currently valued at $11.67 million, has been facing challenges with InvestingPro data showing significant debt levels and negative EBITDA of -$13.03 million in the last twelve months. The transaction, which took place on May 19, 2025, involved Siokas acquiring the shares at a price of $0.429 per share, totaling approximately $33,999. This acquisition was part of a settlement for a $34,000 debt the company owed to Siokas. Following this transaction, Siokas now directly owns 5,661,320 shares of Cosmos Health. The stock, which has declined 37% over the past year, is currently trading below its InvestingPro Fair Value, with analysts expecting profitability in 2025. Investors can access detailed financial analysis and 8 additional ProTips ahead of the company’s earnings report on May 22.
In other recent news, Cosmos Health Inc. has been granted an additional 180-day extension by the Nasdaq Stock Market to meet the minimum bid price requirement, now extended to November 3, 2025. The company has been actively working to regain compliance, aiming to have its stock price reach or exceed $1.00 per share for at least 10 consecutive business days. Additionally, CEO Greg Siokas increased his stake in Cosmos Health by purchasing 1,466,764 common shares for $526,000, bringing his total ownership to over 5.5 million shares. This move underscores his confidence in the company’s value creation.
Cosmos Health also announced a significant contract manufacturing agreement with Pharmex S.A. through its subsidiary Cana Laboratories. This deal involves producing 300,000 bottles annually of the antiseptic drug AMBITASOL 1L over five years. Furthermore, the company has expanded into the Albanian market by launching its Sky Premium Life food supplements brand in partnership with Pharma Cell. The initial order from Pharma Cell is valued at $300,000, with plans to grow the collaboration.
These developments highlight Cosmos Health’s strategic efforts to enhance its manufacturing capabilities and expand its global presence. The company continues to focus on strengthening its operations in Europe, Asia, and North America, leveraging its vertically integrated model and diverse healthcare offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.